Misoprostol is a prostaglandin E1 analogue that has been approved by the Food and Drug Administration (FDA) initially to be taken orally for the prevention & treatment of gastric ulcers. Now the drug is being used successfully in prevention and treatment of postpartum haemorrhage. Two hundredpregnant women at term with spontaneous onset of labour were included in the study and were randomly divided into 2 groups of 100 women each group A and group B were given per rectal misoprostol (600μg) and intramuscularsyntocinon(10U)respectively at that delivery of anterior shoulder of foetus. In misoprostol group, G1 had average blood loss of 250ml, G2 and 228ml of average blood loss, G3 had 210.3ml of blood loss and G4 had average loss of 266.7ml. In Syntocinon group, G1 had average blood loss of 162.7ml, G2 lost154.3ml,G3 lost 171.1ml whereas maximum loss seen in G4 patients which were 200ml. So average blood loss was maximum in 4th gravidaThe p value is >0.05 showing no relation of the effect of parity on blood loss duringthird stage with Misoprost and Syntocinon.